Immune system – indirect, non-specific activation

Immune system – indirect, non-specific activation refers to a therapeutic approach that enhances the body's overall immune response rather than targeting a specific antigen or a single molecular receptor [1]. This category includes agents that stimulate the innate immune system, leading to a cascade of events that can improve the detection and destruction of pathogens or tumor cells [2]. Common examples include bacterial products like the Bacillus Calmette-Guerin (BCG) vaccine used in bladder cancer or chemical agents that induce cytokine production [3]. While these therapies provide a broad defense mechanism, their non-specific nature often results in systemic side effects such as fever, fatigue, and potential autoimmunity [1]. In contemporary pharmacology, many agents previously classified under this category have been found to target specific receptors like Toll-like receptors (TLRs), though the term remains in use for complex biologicals or multi-target stimulants [2]. This approach is particularly relevant in oncology and the treatment of recurrent respiratory infections where a general boost to host defenses is required [3]. Sources: [1] StatPearls: Immunotherapy (https://www.ncbi.nlm.nih.gov/books/NBK538194/); [2] National Cancer Institute: Non-specific immunotherapy (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/non-specific-immunotherapy); [3] Wikipedia: Immunostimulant (https://en.wikipedia.org/wiki/Immunostimulant).

Other names

Non-specific immunotherapyGeneral immunostimulationInnate immune activationBiological response modifiersNon-specific immunomodulation

Broad stimulation of the innate and adaptive immune systems through the activation of macrophages, natural killer (NK) cells, and dendritic cells, leading to the systemic release of pro-inflammatory cytokines and enhanced surveillance against pathogens or malignant cells.